Bicycle Therapeutics PLCNASDAQ:BCYC
- LAST PRICE23.7100
- TODAY'S CHANGE (%)0.0900 (0.3810%)
- Bid / Lots23.7200/ 2
- Ask / Lots23.8400/ 4
- Open / Previous Close23.5100 / 23.6200
- Day Range
- 52 Week Range
- Volume43,039
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | BCYC |
|---|---|---|
| 09:32 ET | 1389 | 23.51 |
| 09:34 ET | 3434 | 23.715 |
| 09:41 ET | 1100 | 23.72 |
| 09:56 ET | 100 | 23.57 |
| 10:06 ET | 130 | 23.64 |
| 10:08 ET | 293 | 23.63 |
| 10:10 ET | 600 | 23.71 |
| 10:12 ET | 700 | 23.81 |
| 10:14 ET | 727 | 23.81 |
| 10:15 ET | 300 | 23.86 |
| 10:17 ET | 400 | 23.86 |
| 10:19 ET | 430 | 23.86 |
| 10:26 ET | 1681 | 23.97 |
| 10:28 ET | 2471 | 23.86 |
| 10:33 ET | 100 | 23.81 |
| 10:53 ET | 100 | 23.71 |
| 10:55 ET | 1589 | 23.775 |
| 10:57 ET | 900 | 23.85 |
| 11:00 ET | 200 | 24.01 |
| 11:08 ET | 100 | 23.82 |
| 11:09 ET | 100 | 23.9 |
| 11:11 ET | 200 | 23.69 |
| 11:13 ET | 200 | 23.79 |
| 11:15 ET | 900 | 23.835 |
| 11:18 ET | 1850 | 23.82 |
| 11:22 ET | 100 | 23.87 |
| 11:27 ET | 100 | 23.87 |
| 11:29 ET | 700 | 23.82 |
| 11:40 ET | 287 | 23.85 |
| 11:42 ET | 600 | 23.72 |
| 11:56 ET | 2696 | 23.67 |
| 12:02 ET | 100 | 23.75 |
| 12:05 ET | 100 | 23.67 |
| 12:14 ET | 200 | 23.68 |
| 12:18 ET | 500 | 23.66 |
| 12:21 ET | 100 | 23.69 |
| 12:23 ET | 500 | 23.66 |
| 12:27 ET | 2486 | 23.64 |
| 12:36 ET | 200 | 23.7199 |
| 12:48 ET | 200 | 23.63 |
| 12:57 ET | 100 | 23.56 |
| 01:01 ET | 350 | 23.635 |
| 01:03 ET | 100 | 23.58 |
| 01:10 ET | 100 | 23.57 |
| 01:17 ET | 349 | 23.5723 |
| 01:24 ET | 300 | 23.635 |
| 01:35 ET | 270 | 23.64 |
| 01:39 ET | 200 | 23.59 |
| 01:48 ET | 100 | 23.62 |
| 01:50 ET | 200 | 23.62 |
| 01:51 ET | 300 | 23.6741 |
| 01:55 ET | 630 | 23.71 |
May 3, 2024
DJ Bicycle Therapeutics Price Target Maintained With a $55.00/Share by HC Wainwright & Co., from 3:29PM ET on Friday May 03, 2024 by Dow Jones
3:29PM ET on Friday May 03, 2024 by Dow Jones
May 2, 2024
Bicycle Therapeutics Reports Recent Business Progress and First Quarter 2024 Financial Results, from 7:00AM ET on Thursday May 02, 2024 by Dow Jones
7:00AM ET on Thursday May 02, 2024 by Dow Jones*DJ Bicycle Therapeutics 1Q Loss/Shr 62c >BCYC, from 7:00AM ET on Thursday May 02, 2024 by Dow Jones
7:00AM ET on Thursday May 02, 2024 by Dow Jones
Apr 24, 2024
Bicycle Therapeutics Announces Two Abstracts Accepted for Presentation at the 2024 ASCO Annual Meeting, from 10:05AM ET on Wednesday Apr 24, 2024 by Dow Jones
10:05AM ET on Wednesday Apr 24, 2024 by Dow Jones
Apr 10, 2024
DJ Bicycle Therapeutics Price Target Maintained With a $43.00/Share by Needham, from 5:32AM ET on Wednesday Apr 10, 2024 by Dow Jones
5:32AM ET on Wednesday Apr 10, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Bicycle Therapeutics PLC | 1.0B | -5.3x | --- |
Immunome Inc | 941.1M | -4.7x | --- |
Relay Therapeutics Inc | 864.1M | -2.4x | --- |
Centessa Pharmaceuticals PLC | 1.1B | -6.0x | --- |
Abcellera Biologics Inc | 1.1B | -7.9x | --- |
Viridian Therapeutics Inc | 951.0M | -3.1x | --- |
Company Information
Bicycle Therapeutics plc is a United Kingdom-based clinical-stage biopharmaceutical company. The Company is developing a class of medicines, which it refers to as Bicycles, for diseases that are underserved by existing therapeutics. Bicycles are therapeutic modality combining the pharmacology usually associated with a biologic with the manufacturing and pharmacokinetic properties of a small molecule. Its product candidates BT5528, BT8009 and BT1718, are each a Bicycle Toxin Conjugate (BTC). BT5528 is a second-generation BTC designed to target Ephrin type A receptor 2 (EphA2). BT8009 is a second-generation BTC designed to target Nectin-4, a validated tumor antigen. BT1718 is being developed to target tumors that express Membrane Type 1 matrix metalloproteinase (MT1 MMP). Its product candidates BT7480 and BT7455, are each a Bicycle tumor-targeted immune cell agonist (TICA). The Company is also focused on additional therapeutic areas other than its wholly owned oncology portfolio.
Contact Information
- Headquarters
- Blocks A & B, Portway Building, Granta PCAMBRIDGE, United Kingdom CB21 6GS
- Phone
- 122-326-1503
- Fax
- ---
Executives
- Non-Executive Chairman of the Board
- Pierre Legault
- Chief Executive Officer, Executive Director
- Kevin Lee
- Chief Financial Officer, Principal Financial Officer
- Alethia Young
- Chief Operating Officer
- Alistair Milnes
- Chief Technology Officer
- Michael Skynner
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $1.0B |
|---|---|
Revenue (TTM) | $41.6M |
Shares Outstanding | 42.8M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.90 |
EPS | $-4.45 |
Book Value | $8.74 |
P/E Ratio | -5.3x |
Price/Sales (TTM) | 24.3 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -432.25% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
